The Influence of Prior Hyperthyroidism on Euthyroid Graves’ Ophthalmopathy

Table 4

Therapy for Graves’ hyperthyroidism and Graves’ ophthalmopathy.

Therapy	Group A; (𝑁=37)	Group B; (𝑁=41)	𝑃 Value
Smoking cessation	3/16 (19%)	4/18 (22%)	NS^†
Antithyroid drugs	—	22 (54%)	—
Thyroidectomy	—	2 (5%)	—
Radioiodine	—	33 (80%)	—
Orbital irradiation	3 (8%)	0 (0%)	NS^†
Corticosteroids^‡	2 (5%)	2 (5%)	NS^†
Orbital decompression	1 (3%)	5 (12%)	NS^†
Strabismus surgery	7 (19%)	12 (29%)	NS^†
Upper eyelid blepharoplasty	2 (5%)	4 (10%)	NS^†
Upper eyelid lengthening surgery	6 (16%)	4 (10%)	NS^†

Values are expressed as numbers, except as if indicated.
^†NS = not significant.
^‡For moderate-to-severe GO: methylprednisolon 64 mg/d orally, with taper over 2-3 months and for 1 patient in group B with dysthyroid optic neuropathy: methylprednisolon intravenously 6×1000 mg/d over 2 weeks, with taper orally.